Abstract: The present invention generally relates to a mixing nozzle (12) for mixing at least two liquid compositions such as a first liquid composition and a second liquid composition. The mixing nozzle (10) is configured to be coupled to a body (11) of a multi-component application device (10), in particular to a body (11) of a two-component syringe assembly, for injection of a liquid composition, which body (11) is configured to separately store said at least two solutions. The present invention further relates to a multi-component application device (10) comprising said mixing nozzle (12) and to a kit comprising said mixing nozzle (12) or said application device (10). Furthermore, the present invention relates to a method using said application device or said kit, for example for replacing or filling a biological tissue or increasing the volume of a biological tissue.

Abstract: A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

Abstract: A powder formulation, or pharmaceutical composition comprising or consisting of particles of an antimuscarinic agent, said particles being obtainable by supercritical anti-solvent (SAS) precipitation and having a D50 of 4 ?m or less and a D90 of 10 ?m or less. Methods of forming the formulation and composition are also disclosed, as are uses of the composition.

Abstract: Described herein is a composition for submucosal injection comprises a biocompatible modified starch and a pharmaceutically acceptable carrier for injection. The biocompatible modified starch is in an amount ranging from 0.2 wt % to 50 wt % of the total weight of composition. The biocompatible modified starch is selected from one or more of the group consisting of: etherified starches, esterified starches, cross-linked starches, pre-gelatinized starches, graft starches and composite modified starches, which has a molecular weight ranging from 3,000 to 2,000,000 daltons, a water absorbency capability of at least twice of its own weight, and a particle size from 500 nm to 1000 ?m. The viscosity of the composition ranges from 9 mPa·s to 150,000 mPa·s at 25° C. The present disclosure also provides a combination reagent for submucosal injection, comprising the above-mentioned biocompatible modified starch and the pharmaceutically acceptable carrier for injection.

Abstract: A hemostatic composition of matter includes a coherent blend of collagen fibrils combined with starch particles as a fluffy mass with hemostatic properties better than collagen fibrils alone or starch particles alone, the composition exhibiting a level of coherence wherein the composition can be lifted, without crushing fibrils, without loss of more than 5% of 10% of a total weight of starch particles from the composition. Sheets with less than 10% by weight of additional binder are also disclosed.

Abstract: Cyphomycin, an isolated compound of Formula I or IA is provided. A compound isolated from insect Streptomyces and having a chemical formula of C77H122O26 is also provided. Compositions including Cyphomycin, such as pharmaceutical compositions including effective amounts of Cyphomycin for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Cyphomycin and compositions thereof are disclosed.

Abstract: Combination powdered material, including a first powder composition and a second powder composition, the first powder composition including cellulose particulate material and the second powder composition including starch particles, alone or in combination with talc particles.

Abstract: The present disclosure relates to barley plants having grain with ultra-high beta-glucan content, methods for constructing said barley plants, grain therefrom and uses thereof. In an exemplary embodiment, present disclosure provides a barley plant having grain with ultra-high beta-glucan content known as CM1.

Abstract: To provide an IgA production promoter capable of being easily ingested safely and continually, for example orally and capable of preventing infection by inhibiting the binding of pathogenic microorganisms to alimentary canal mucosa and preventing an allergic reaction by blocking the passage of allergen materials such as pollen and house dust through the wall of the alimentary tract. The present invention consists of an IgA production promoter comprising hydroxypropyl starch as an effective ingredient. The IgA production promoter of the present invention can be safely and continually ingested because the effective ingredient thereof is hydroxypropyl starch used in food and the like, and can prevent infection by inhibiting the binding of pathogenic microorganisms to alimentary canal mucosa and prevent an allergic reaction by blocking the passage of allergen materials such as pollen and house dust through the wall of the alimentary tract.

Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (R; A), (ii) at least one reverse-flight section (D), and (iii) a discharging section (E), wherein the processing elements defining the reverse-flight section (R; D) comprise at least one reverse-flight element (14) which is based on a screw-type element having a conveying direction being opposite to the general conveying direction of the extruder.

Abstract: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements disposed axially one behind the other, the processing elements defining (i) a feeding and conveying section (A), (ii) at least one mixing section (B), and (iii) a discharging section (E), wherein the processing element(s) defining the mixing section (B) comprise(s) a mixing element (11, 12, 13) that is derived from a screw type element (FIG. 2).

Abstract: The invention relates generally to mouth rinses for the prevention and elimination of bad breath as well as for the reduction of oral microorganisms responsible for the development of dental plaque and tooth decay. In particular, the present invention relates to a non-alcohol or reduced alcohol mouth rinses effective at preventing the above-mentioned problems.

Abstract: The present invention provides a composition comprising a hyaluronic acid derivative having a crosslinking group(s) and a hydrophilic polysaccharide derivative having a hydrophobic group(s), wherein the hyaluronic acid derivative having a crosslinking group(s) is prepared by crosslinkage formation reaction in hyaluronic acid or a derivative thereof having a crosslinkable group(s) in the presence of the hydrophilic polysaccharide derivative wherein the hydrophilic polysaccharide derivative may have a crosslinkable group(s).

Abstract: Peritoneal dialysis solutions including a glucose polymer and methods of using the dialysis solutions are disclosed herein. In a general embodiment, the peritoneal dialysis solution includes a glucose polymer in an amount to provide an increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed compared to conventional dialysis solutions containing icodextrin as the active pharmaceutical ingredient. The increased ultrafiltration fluid volume for a given amount of carbohydrate absorbed is obtained by providing specific combinations of weight-average molecular weight, polydispersity index and concentration of the glucose polymer in the dialysis solution.

Abstract: Compositions of matter are provided that include chitosan and a modified carbohydrate. The modified carbohydrate includes a carbohydrate component and a cross linking agent. The modified carbohydrate has increased carboxyl content as compared to an unmodified counterpart carbohydrate. A carboxyl group of the modified carbohydrate is covalently bonded with an amino group of chitosan. The compositions of matter provided herein may include cross linked starch citrate-chitosan and cross linked hemicellulose citrate-chitosan, including foams thereof. These compositions yield excellent absorbency and metal chelation properties. Methods of making cross linked modified carbohydrate-chitosan compounds are also provided.

Abstract: A hydrogel tissue adhesive having decreased degradation time is described. The hydrogel tissue adhesive is formed by reacting an oxidized polysaccharide with a water-dispersible, multi-arm polyether amine in the presence of an oligomer additive, which promotes the degradation of the hydrogel. The hydrogel may be useful as a tissue adhesive or sealant for medical applications, such as a hemostat sealant or to prevent undesired tissue-to-tissue adhesions resulting from trauma or surgery.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

Abstract: The invention relates to a compound, comprising a) a first starch derivative selected from the group consisting of hydroxyalkyl starch, carboxyl alkyl starch, ester starch and arbitrary mixtures thereof, wherein the starch derivative has a mean relative molar mass Mw1 and a degree of molar substitution MS1, and b) a second starch derivative selected from the group consisting of hydroxyalkyl starch, carboxyl alkyl starch, ester starch and arbitrary mixtures thereof, having a mean relative molar mass Mw2 and a degree of molar substitution MS2, characterized in that Mw1 is greater than Mw2 (Mw1>Mw2) and MS2 is greater than MS1 (MS2>MS1).

Abstract: Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain Nitrogen containing polymers (e.g., Polylysine, Polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.

Abstract: The present invention provides a solution for peritoneal dialysis, consisting of at least two single solutions which are combined after a heat sterilization and are administered to a patient, the first single solution containing an osmotic and the second single solution containing a buffer, and one of these single solutions or another single solution containing electrolyte salts. Glucose-like degradation and hydrolysis is avoided during sterilization and storage, while maintenance of a neutral mixture pH is achieved by the osmotic comprising a glucose polymer and/or glucose polymer derivative, and the pH of the first single solution being between 3.5 and 5.0. The present invention further discloses a twin-chambered pouch consisting of a plastic pouch with at least one first chamber and a second chamber, the first single solution being included in the first chamber and the second single solution being included in the second chamber.

Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

Abstract: Universal sensory structurants and compositions comprising the same are described. The universal sensory structurants comprise polysaccharide carbohydrate having at least about 75% by weight amylopectin and the polysaccharide carbohydrate has been treated and swollen with a solvent comprising hydroxylated polymer comprising less than about 100 silane repeat units.

Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.

Abstract: A method of treating constipation is disclosed. The method includes administering starch-entrapped microbeads.

Abstract: A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery.

Abstract: Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon.

Abstract: Biodegradable materials are formed by mixing together two or more materials which have different resorption times and different mechanical characteristics. Devices formed of these materials can be used in mammals in numerous medical and surgical applications, including those for which the mechanical properties of the device, left in vivo, much change over time.

Abstract: The present invention relates to a composition for preventing tissue adhesion which comprising a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has not been modified by a chemical crosslinking or other chemical modification a method for preparing the same, and a composition for adhesion prevention with superior efficacy. The composition of the present invention for preventing adhesion exhibits a physical barrier function and a new adhesion prevention function whereby thrombus formation, which is the basis of adhesion, is inhibited.

Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.

Abstract: A composition for forming a temporary intestinal occlusion in a mammal is flowable and solidifiable to form a solid plug at a predetermined site in the intestine, the structure of the plug being changeable to allow for a subsequent, at least partial removal of the occlusion. The composition is or comprises a flowable solution, suspension, or dispersion in a solvent or mixed solvent, and comprises the following: a) a suspension of a solid in water or an aqueous mixed solvent, the suspension having a water content which exceeds the flow limit of the suspension by a specific amount; b) a dehydrating agent in an amount which is sufficient to bind the specific amount of water, so that, as a consequence of dehydration, the flow limit of the suspension is exceeded; and c) a means for passivating the dehydrating agent.

Abstract: The present invention relates to nitric oxide delivering hydroxyalkyl starch derivatives, methods of preparing the same, and specific uses of these hydroxyalkyl starch derivatives.

Abstract: The invention provides methods for promoting weight loss by an animal, promoting weight loss by an animal while preventing or minimizing loss of lean body mass by the animal preventing a reduction in energy metabolism by an animal reducing the risk of regaining weight by an animal after weight loss, and ameliorating undesirable animal behaviors associated with reduced caloric intake by intermittently feeding an animal a first diet containing calories that meet the animal's maintenance energy requirements and a second diet containing calories that do not meet the animal's maintenance energy requirements. In preferred embodiments, the described feeding pattern and diets are ted in conjunction with one or more weight loss agents.

Abstract: Provided herein is an anhydrous cosmetic composition comprising at least one organic structuring agent, at least one modified starch, at least one wood meal, at least one surfactant, and at least one anhydrous liquid phase. Also provided is a method for cleansing and/or conditioning keratin materials, comprising applying at least one of the anhydrous cosmetic compositions to the keratin materials.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: One aspect of the invention is a method of treating a wound to clot blood. A sponge material is applied to the wound. The sponge comprises a starch having hemostatic properties and at least one binding agent. The sponge may further comprise a porous, flexible material.

Abstract: Provided herein are methods of treating, suppressing, inhibiting, or preventing bronchitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

Abstract: The present invention relates to hydroxyalkylstarch (HAS)-polypeptide-conjugate (HAS-polypeptide) comprising one or more HAS molecules, wherein each HAS is conjugated to the polypeptide via a carbohydrate moiety or a thioether as well as to methods for the production thereof. In a preferred embodiment, the polypeptide is erythropoietin (EPO).

Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.

Abstract: Methods and compositions for potentiating the sonothrombolysis of a thrombus within a circulatory vessel of a patient are described. In particular, a method of performing sonothrombolysis in which a suspension that may include microbubbles, degradable starch nanoparticles, and a tissue permeabilizer is administered to the patient in tandem with the directing of ultrasound pulses at the thrombus is described.

Abstract: The subject matter of the present invention is a sterile liquid composition dedicated to administration into or through the skin and/or the lips, wherein said composition comprises, in a physiologically acceptable medium, at least one photo-crosslinkable compound, wherein said compound comprises at least one activated photo-dimerizable group having at least one activated double bond and selected from photo-dimerizable groups carrying a stilbazolium function of formula (Ia) or (Ib) and wherein the photo-dimerizable groups carry a styrylazolium function of formula (II), the photo-dimerizable group(s) being carried by a partially or totally hydrolysed poly(vinyl acetate) polymer, a polysaccharide or a polyvinyl alcohol

Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: Described are a hydroxyethylstarch, a process for the preparation thereof, a pharmaceutical formulation containing such a hydroxyethylstarch, and the use of the pharmaceutical formulation for the preparation of a volume replacement, a plasma replacement or a plasma volume expander, as well as the use of the pharmaceutical formulation for maintaining normovolemia and/or for improving the macro- and microcirculation and/or for improving the nutritive oxygen supply and/or for stabilizing hemodynamics and/or for improving the volume efficiency and/or for reducing the plasma viscosity and/or for increasing anemia tolerance and/or for hemodilution, especially for therapeutic hemodilution in disturbed blood supply and arterial, especially peripheral arterial, occlusive diseases.

Abstract: Compositions which provide slowly digestible starch and a source of fermentable dietary fiber. Microparticles in which starch is entrapped in a crosslinked matrix to provide dietary benefit. Such microparticles are used to deliver glucose to targeted regions in the small intestine for beneficial physiological effects, and fermentable dietary fiber to the colon to improve colon health and to treat diseases of the colon. Microparticles can be employed to selectively deliver fermentable dietary fiber to targeted portions of the colon. A method for making the microparticles is provided as well as methods for using the microparticles for controlled digestion of starch on ingestion in the small intestine and methods for using the microparticles to deliver dietary fiber. The microparticles with entrapped starch provide a low glycemic index and extended glucose release in food products and food ingredients.

Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.

Abstract: Methods of controlling serum glucose levels in an individual are described, the methods including the step of administering to said individual a therapeutic food composition comprising a waxy and/or hydrothermally treated starch. The method may be used to treat or prevent hypoglycaemia in patients susceptible to hypoglycaemic episodes, for example patients with glycogen storage disease, diabetes or liver disease. The method may also be used in sports nutrition. Also described are compositions for use in the methods.

Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.